84773-28-4

Basic information

• Product Name: (R)-2-(METHYLAMINO)-2-PHENYLETHANOL
• Synonyms: (R)-2-(METHYLAMINO)-2-PHENYLETHANOL
• CAS NO: 84773-28-4
• Molecular Formula: C₉H₁₃NO
• Molecular Weight: 151.20562
• Mol File: 84773-28-4.mol
• Article Data: 11

Chemical Properties

• Melting Point: 53-56 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 270.0±20.0 °C(Predicted)
• Appearance: /
• Density: 1.036±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.52±0.10(Predicted)
• CAS DataBase Reference: (R)-2-(METHYLAMINO)-2-PHENYLETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-(METHYLAMINO)-2-PHENYLETHANOL(84773-28-4)
• EPA Substance Registry System: (R)-2-(METHYLAMINO)-2-PHENYLETHANOL(84773-28-4)

Safety Data

• Hazardous Substances Data: 84773-28-4(Hazardous Substances Data)

Usage

Description

(R)-2-(METHYLAMINO)-2-PHENYLETHANOL, with the molecular formula C9H13NO, is an enantiomer of 2-(methylamino)-2-phenylethanol. This white to off-white solid at room temperature is recognized for its mild, floral aroma. It is a valuable chiral auxiliary in organic synthesis, playing a crucial role in the creation of pharmaceuticals with chiral structures.
Used in Pharmaceutical Industry:
(R)-2-(METHYLAMINO)-2-PHENYLETHANOL is used as a chiral auxiliary for the synthesis of pharmaceuticals with chiral structures. Its unique properties allow for the development of new chemical entities that are essential in the pharmaceutical industry.
Used in Fragrance and Flavor Industry:
(R)-2-(METHYLAMINO)-2-PHENYLETHANOL is used as a key ingredient in the production of fragrances and flavors due to its distinctive and appealing odor. This makes it a valuable component in creating a wide range of scented and flavored products.

Upstream product

• 161533-41-1 ethyl (1R)-2-hydroxy-1-phenylethylcarbamate 
• 10419-71-3 (2R)-2-(N-formyl)amino-2-phenylacetic acid 
• 90319-52-1 (4R)-phenyl-2-oxazolidinone 
• 30925-14-5 (R)-(-)-α-methylamino phenylacetic acid 
• 67341-01-9 (R)-N-(tert-butoxycarbonyl)phenylglycinol 
• 875-74-1 D-α-phenylglycine 
• 19883-41-1 D-phenylglycine methyl ester hydrochloride 
• 56613-80-0 D-2-phenylglycinol 
• 875-74-1 (R)-phenylglycine 
• 27786-19-2 (2R)-[(ethoxycarbonyl)amino](phenyl)acetic acid 
• 78247-61-7 formylamino-acetic acid methyl ester 
• 10419-71-3 Formylamino-phenyl-acetic acid 

Downstream Products

• 139437-51-7 (2S,4R)-2-Furan-2-yl-3-methyl-4-phenyl-oxazolidine 
• 139437-51-7 (2R,4R)-2-Furan-2-yl-3-methyl-4-phenyl-oxazolidine 
• 139437-53-9 (2R,4R)-3-Methyl-4-phenyl-2-thiophen-3-yl-oxazolidine 
• 160247-39-2 {[((R)-2-Hydroxy-1-phenyl-ethyl)-methyl-carbamoyl]-methyl}-methyl-carbamic acid tert-butyl ester 
• 84694-29-1 2-phenyl>-3-methyl-4(R)-phenyloxazolidine 
• 870002-63-4 (2R)-2-(N-methyl-N-nitroso)amino-2-phenylethanol 
• 157586-97-5 (R)-3-Methyl-4-phenyl-[1,2,3]oxathiazolidine 2,2-dioxide 
• 160247-31-4 (R)-N-(2-hydroxy-1-phenylethyl)-N-methyl-butanamide 
• 143490-16-8 (2S,4R)-2-(2-bromophenyl)-3-methyl-4-phenyl-1,3-oxazolidine 
• 143490-16-8 (2R,4R)-2-(2-bromophenyl)-3-methyl-4-phenyl-1,3-oxazolidine 
• 272112-21-7 2-benzo[1,3]dioxol-5-yl-N-(2-hydroxy-1-phenyl-ethyl)-N-methyl-acetamide 
• 272112-22-8 2-(3,4-dimethoxy-phenyl)-N-(2-hydroxy-1-phenyl-ethyl)-N-methyl-acetamide 
• 160247-37-0 N-[(R)-2-hydroxy-1-phenylethyl]-N-methyl-2-phenylacetamide 
• 317820-95-4 (E)-4-[((R)-2-Hydroxy-1-phenyl-ethyl)-methyl-amino]-but-2-enoic acid methyl ester 

Relevant articles and documents

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as "APSAP compounds"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.